Rapid effects of zoledronic acid in reducing bone complications in patients with bone metastases in the first 3 months of treatment

被引：0
|
作者：
Saad, F.
Chen, Y. M.
机构：
[1] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
[2] Novartis Oncol, E Hanover, NJ USA
来源：
CANCER TREATMENT REVIEWS | 2006年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
131
引用
收藏
页码：S51 / S52
页数：2
相关论文
共 50 条
  • [41] Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases
    Tas, Faruk
    Duranyildiz, Derya
    Oguz, Hilal
    Camlica, Hakan
    Yasasever, Vildan
    Topuz, Erkan
    MEDICAL ONCOLOGY, 2008, 25 (03) : 346 - 349
  • [42] NTX and VEGF in cancer patients with bone metastases treated with zoledronic acid
    Mercatali, L.
    Ibrahim, T.
    Sacanna, E.
    Ricci, R.
    Scarpi, E.
    Fabbri, F.
    Serra, P.
    Tison, C.
    Amadori, D.
    EJC SUPPLEMENTS, 2010, 8 (05): : 23 - 23
  • [43] Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases
    Faruk Tas
    Derya Duranyildiz
    Hilal Oguz
    Hakan Camlica
    Vildan Yasasever
    Erkan Topuz
    Medical Oncology, 2008, 25 : 346 - 349
  • [44] Zoledronic acid effect on bone metabolic markers in patients with bone metastases due to lung cancer
    Rabinowits, G.
    Janckila, A.
    Yam, L.
    Hendler, F.
    Kloecker, G. H.
    CLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 : 46 - 47
  • [45] Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases
    Serefoglu, Ege Can
    Balbay, M. Derya
    MEDICAL HYPOTHESES, 2009, 73 (03) : 387 - 388
  • [46] Long-term safety of zoledronic acid for the treatment of patients with breast cancer and bone metastases
    Lipton, A.
    Dewar, R.
    Conte, R.
    Zheng, M.
    EJC SUPPLEMENTS, 2004, 2 (03): : 142 - 142
  • [47] Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies
    Cameron, D
    BREAST, 2003, 12 : S22 - S29
  • [48] Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases - Analysis of a national medical claims database
    Hatoum, Hind T.
    Lin, Swu-Jane
    Smith, Mathew R.
    Barghout, Victoria
    Lipton, Allan
    CANCER, 2008, 113 (06) : 1438 - 1445
  • [49] Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study
    Stopeck, A.
    Body, J. J.
    Fujiwara, Y.
    Lipton, A.
    Steger, G. G.
    Viniegra, M.
    Fan, M.
    Braun, A.
    Dansey, R.
    Jun, S.
    EJC SUPPLEMENTS, 2009, 7 (03): : 2 - 3
  • [50] Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases
    Body, J.-J.
    Lichinitser, M.
    Tjulandin, S.
    Garnero, P.
    Bergstroem, B.
    ANNALS OF ONCOLOGY, 2007, 18 (07) : 1165 - 1171
12345